Immutep Ltd
eftilagimod alfa (efti)
metastatic breast cancer
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for eftilagimod alfa (efti) in metastatic breast cancer are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 14h ago
“Strong response rates and immune activation in heavily pretreated metastatic breast cancer patients from AIPAC-003 Phase II presented at 2025 San Antonio Breast Cancer Symposium”